{"meta":{"totalResults":3,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Jobevne"},{"type":"CodeName","name":"SIBP04"},{"type":"Synonym","name":"bevacizumab-maly"},{"type":"USBrandName","name":"Alymsys"},{"type":"Synonym","name":"bevacizumab biosimilar RPH-001"},{"type":"Synonym","name":"recombinant humanized anti-VEGF monoclonal antibody"},{"type":"Synonym","name":"BP102 biosimilar"},{"type":"Synonym","name":"bevacizumab biosimilar QL 1101"},{"type":"Synonym","name":"bevacizumab biosimilar CT-P16"},{"type":"Synonym","name":"anti-VEGF humanized monoclonal antibody"},{"type":"Synonym","name":"bevacizumab biosimilar FKB238"},{"type":"Synonym","name":"bevacizumab biosimilar LY01008"},{"type":"Synonym","name":"immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMab-VEGF light chain, dimer"},{"type":"Synonym","name":"anti-VEGF rhuMAb"},{"type":"USBrandName","name":"Mvasi"},{"type":"Synonym","name":"bevacizumab biosimilar BEVZ92"},{"type":"Synonym","name":"bevacizumab biosimilar HLX04"},{"type":"CodeName","name":"HD204"},{"type":"Synonym","name":"bevacizumab awwb"},{"type":"Synonym","name":"bevacizumab biosimilar HD204"},{"type":"Synonym","name":"bevacizumab biosimilar ABP 215"},{"type":"Synonym","name":"bevacizumab biosimilar IBI305"},{"type":"Synonym","name":"bevacizumab biosimilar QL1101"},{"type":"USBrandName","name":"Avastin"},{"type":"Synonym","name":"bevacizumab biosimilar MIL60"},{"type":"Synonym","name":"bevacizumab biosimilar MYL-1402O"},{"type":"CodeName","name":"BP102"},{"type":"Synonym","name":"bevacizumab biosimilar BI 695502"},{"type":"Synonym","name":"bevacizumab biosimilar Zirabev"},{"type":"CodeName","name":"ABP 215"},{"type":"CodeName","name":"MYL-1402O"},{"type":"CodeName","name":"SCT501"},{"type":"USBrandName","name":"Zirabev"},{"type":"Synonym","name":"bevacizumab biosimilar GB-222"},{"type":"Abbreviation","name":"rhuMab-VEGF"},{"type":"Synonym","name":"bevacizumab biosimilar CBT 124"},{"type":"Synonym","name":"bevacizumab biosimilar SCT501"},{"type":"CASRegistryName","name":"216974-75-3"},{"type":"Synonym","name":"anti-VEGF monoclonal antibody SIBP04"},{"type":"CodeName","name":"QL1101"},{"type":"CodeName","name":"SIBP 04"},{"type":"CodeName","name":"SIBP-04"},{"type":"CodeName","name":"BAT 1706"},{"type":"CodeName","name":"BAT-1706"},{"type":"CodeName","name":"BAT1706"},{"type":"Synonym","name":"BAT1706 biosimilar"},{"type":"Synonym","name":"bevacizumab biosimilar Mvasi"},{"type":"Synonym","name":"bevacizumab-adcd"},{"type":"CodeName","name":"CT-P16"},{"type":"ForeignBrandName","name":"Vegzelma"},{"type":"Synonym","name":"bevacizumab biosimilar BAT1706"}],"definition":{"html":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","text":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/bevacizumab","text":"Bevacizumab"},"nciConceptId":"C2039","nciConceptName":"Bevacizumab","termId":43234,"name":"bevacizumab","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"bevacizumab"},{"aliases":null,"definition":{"html":"An immunoconjugate and a fluorescent tracer consisting of the recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab conjugated to the N-hydroxysuccinamide (NHS) ester form of the near-infrared (NIR) fluorescent dye IRDye 800CW, that may be used for VEGF-specific tumor imaging. Upon administration, the bevacizumab moiety of bevacizumab-IRDye 800CW binds to VEGF and the fluorescent signal can be visualized using NIR fluorescence imaging (700–1,000 nm).","text":"An immunoconjugate and a fluorescent tracer consisting of the recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab conjugated to the N-hydroxysuccinamide (NHS) ester form of the near-infrared (NIR) fluorescent dye IRDye 800CW, that may be used for VEGF-specific tumor imaging. Upon administration, the bevacizumab moiety of bevacizumab-IRDye 800CW binds to VEGF and the fluorescent signal can be visualized using NIR fluorescence imaging (700–1,000 nm)."},"drugInfoSummaryLink":null,"nciConceptId":"C101261","nciConceptName":"Bevacizumab-IRDye 800CW","termId":729590,"name":"bevacizumab-IRDye 800CW","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"bevacizumab-irdye-800cw"},{"aliases":[{"type":"Synonym","name":"carboplatin-paclitaxel-bevacizumab regimen"},{"type":"Synonym","name":"carboplatin-Taxol-bevacizumab regimen"},{"type":"Synonym","name":"carbo-Taxol-Avastin regimen"},{"type":"Synonym","name":"carboplatin-paclitaxel-bevacizumab"},{"type":"Synonym","name":"carboplatin-Taxol-bevacizumab"},{"type":"Synonym","name":"carboplatin/paclitaxel/bevacizumab"}],"definition":{"html":"A regimen consisting of bevacizumab, carboplatin and paclitaxel that can be used in the treatment of endometrial, ovarian, fallopian tube and primary peritoneal, vulvar and cervical cancers and non-small cell lung cancer (NSCLC).","text":"A regimen consisting of bevacizumab, carboplatin and paclitaxel that can be used in the treatment of endometrial, ovarian, fallopian tube and primary peritoneal, vulvar and cervical cancers and non-small cell lung cancer (NSCLC)."},"drugInfoSummaryLink":null,"nciConceptId":"C63413","nciConceptName":"Bevacizumab/Carboplatin/Paclitaxel Regimen","termId":657275,"name":"bevacizumab/carboplatin/paclitaxel regimen","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"bevacizumab-carboplatin-paclitaxel-regimen"}],"links":null}